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ABSTRACT
Objective Neovascular age- related macular 
degeneration (nAMD) causes damage to the macula and 
severe vision loss. Bevacizumab is the most cost- effective 
nAMD treatment. The TANDEM trial was designed to 
determine whether, in patients with nAMD, low- dose 
bevacizumab is non- inferior to the standard dose in terms 
of visual deterioration and whether a bimonthly regimen is 
non- inferior to monthly, treatment as required, regimens.
Methods This was a multicentre, 2×2 factorial, double- 
masked, non- inferiority randomised trial with patients 
considered eligible if they met the National Institute for 
Health and Care Excellence criteria for nAMD treatment 
with ranibizumab. Participants were randomly assigned to 
standard (1.25 mg) or low (0.625 mg) dose bevacizumab 
and either monthly or bimonthly review regimen. The 
primary outcome was time to vision deterioration, defined 
as reduction of ≥15 letters (three lines) during the loading 
phase (visual acuity scores at visits B and C compared 
with the initial visit A), or ≥6 letters (one line) during the 
maintenance phase (visual acuity scores at subsequent 
visits compared with mean vision at visits A–C).
Results In total 812 participants (918 eyes) were 
randomised into the trial. The low dose showed some 
evidence of being non- inferior to standard dose (HR 
1.07; 95% CI 0.80 to 1.42), however, there was no strong 
evidence of bimonthly review being non- inferior to monthly 
review (HR 1.45; 95% CI 1.09 to 1.94). There was no 
difference in visual acuity when assessed at 9 months and 
no major differences in the frequency of serious adverse 
events or reactions between the groups.
Conclusion The standard dose of bevacizumab can be 
halved without compromising efficacy. Bimonthly review 
cannot be considered to be no worse than monthly review.
INTRODUCTION
Neovascular age- related macular degener-
ation (nAMD) is a major UK public health 
issue.1 Untreated, nAMD has a poor prog-
nosis with average visual loss of 1–3 lines at 
3 months from diagnosis and 3–4 lines by 
1 year.2
Introduction of the angiogenesis inhibi-
tors, bevacizumab (Avastin) and ranibizumab 
(Lucentis) has transformed the prognosis for 
nAMD.3 A major issue for treatment is cost, 
with bevacizumab being much cheaper than 
ranibizumab,3 although a barrier to use of 
these agents is the requirement for monthly 
visits; reducing this to bimonthly would 
greatly ease the burden. This led the East 
Midlands Central Commissioning Group to 
commission the TANDEM trial.4
At trial inception, other trials,5–8 to investi-
gate whether bevacizumab was non- inferior to 
ranibizumab were being planned; and there 
Key messages
What is already known about this subject?
 ► Research into neovascular age- related macular 
degeneration (nAMD) treatment had identified that 
bevacizumab (Avastin) and ranibizumab (Lucentis) 
were equally effective treatments.
 ► This trial examined the difference in visual acui-
ty and adverse events between standard, low and 
monthly and bimonthly doses.
What are the new findings?
 ► Our trial demonstrated that the standard dose of 
bevacizumab can be halved without compromising 
efficacy but bimonthly treatment schedule did not 
demonstrate non- inferiority to monthly treatment.
 ► No differences were found in the visual acuity of 
participants at 9 months or major differences with 
reported serious adverse events between the two 
groups.
How might these results change the focus of 
research or clinical practice?
 ► These results provide useful information for clini-
cians patients about the dose and frequency of bev-
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was already strong clinical evidence to confirm that this 
was probably the case.4 This trial aimed to complement 
these studies.
Rationale for low dose treatment arms and the issue of 
systemic safety
The most commonly used dose of Avastin (1.25 mg) 
relies on the assumption that the dose should be equi-
molar to Lucentis, failing to take into account the fact 
that Avastin has two binding sites to vascular endothelial 
growth factor (VEGF) whereas Lucentis, being the Fab 
fragment, only has one. Increasing the dose of Avastin 
to 2.5 mg has shown no increased clinical benefit when 
used to treat AMD.9 10 Moreover, diabetes research has 
found evidence that a lower dose may be just as effective 
with proliferative disease responding to an injected dose 
as low of 0.00625 mg (6.25 µg).11
Results from previous research had identified some 
safety concerns with bevacizumab5 6; however, the 
Cochrane collaboration has concluded that the standard 
dose (1.25 mg) of bevacizumab and the 0.5 mg dose of 
ranibizumab have similar safety profiles. However, both 
carry the risk of systemic side effects, most importantly 
of stroke,12 13 so it is desirable to give the smallest effec-
tive dose. A previous study had found that increasing the 
dose of bevacizumab has no added benefit10 but research 
into reducing the dose had not been conducted.
Rationale for the bimonthly review arms and PRN regimens
Bevacizumab is an IgG monoclonal antibody directed 
against VEGF and ranibizumab was derived from the 
Fab fragment. Whole antibodies persist for months in 
the body whereas fragments are cleared rapidly. In 
humans, the reported half- life of bevacizumab is 10 
days14 compared with the reported 3- day half- life for 
ranibizumab in primate eyes.15 Previous research16 
showed that patients monitored and treated with beva-
cizumab on a 6- weekly basis had similar results to the 
ranibizumab trials.17 18 Aflibercept, which also retains 
the IgG Fc portion, has also been shown to be effective 
when given bimonthly.19
Similar results to previous trials17 18 have also been 
achieved without continuous dosing. The PrONTO, study 
showed this with a monthly pro re nata (PRN) regimen, 
tailoring retreatments to morphological parameters with 
comparable visual acuity (VA) outcomes.20 21
This trial aimed to investigate whether a low dose 
(0.625 mg) of bevacizumab was not inferior to standard 
dose (1.25 mg) in nAMD and whether a bimonthly review 
interval was not inferior to a monthly review interval.
MATERIALS AND METHODS
Study design
We undertook a prospective, multicentre, 2×2 factorial, 
non- inferiority randomised trial in five UK National 
Health Service (NHS) hospitals.
Patients and public involvement
The team consulted patients and local charities at the 
outset of this research and during the trial a member of 
the Macular Society joined the trial independent steering 
committee. Once the trial has been published, partici-
pants will be informed of the results via posters displayed 
throughout the recruiting clinics.
Participants
Participants were adults over the age of 50 years with 
active nAMD who met the National Institute for Health 
and Care Excellence (NICE) criteria for treatment with 
ranibizumab.22 Participants were offered fundus fluo-
rescein angiography (FFA) to confirm the diagnosis, 
which was submitted for independent assessment by the 
UK Network of Ophthalmic Reading Centres’ Central 
Administrative Research Facility (CARF). Participants 
had refraction at baseline to obtain their best- corrected 
VA. Refraction is not standard practice in the NHS and 
those patients whose pretrial vision improved to 6/12 
(logMAR 0.3) or better, remained eligible so as not to be 
disadvantaged. Participation in the trial was not limited 
to one eye, if both eyes were eligible for inclusion at 
baseline then both were enrolled. If during participa-
tion the fellow eye developed nAMD, it too was eligible 
and received treatment as part of the trial. Participants 
who were inactive following a period of 6 months without 
treatment were able to rejoin the trial. Both fellow eyes 
and rejoining eyes were not rerandomised and were 
treated according to the original treatment allocation 
(both dose and review schedule).
Full eligibility criteria have been reported previously.4
Between 29 November 2011 and 15 May 2012, trial 
coordination transferred from Bristol Clinical Trials and 
Evaluation Unit to the Nottingham Clinical Trials Unit; 
trial recruitment was suspended during this time.
Randomisation and masking
Participants were randomly assigned (1:1:1:1) to one of 
four groups in a factorial design: bevacizumab standard 
dose on monthly review, bevacizumab standard dose on 
bimonthly review, bevacizumab low dose on monthly 
review or bevacizumab low dose on bimonthly review. A 
secure web- based allocation schedule was used, stratified 
by centre and blocked using random permuted blocks 
of varying size. Study participants, investigators, clinical 
assessors and injectors were masked to drug dose alloca-
tion throughout the trial, with the visit review masked for 
the loading visits which took place monthly for the first 
3 months. Once randomised, it was not possible to mask 
the participant’s visit review schedule. Masking of dose 
allocation was maintained for participants and clinical 
staff as the pharmacies dispensed the appropriate dose to 
the ophthalmic clinic, in a trial labelled prefilled syringe.
Outcomes
The primary outcome was time to vision deterioration, 
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the loading phase (VA scores at visits B and C compared 
with the initial visit A), or ≥6 letters (one line) during 
the maintenance phase (VA scores at subsequent visits 
compared with mean vision at visits A–C).
The loading phase primary outcome definition (reduc-
tion of ≥15 letters (three lines)), before baseline vision 
was established, was needed to ensure patient safety. The 
trial began before results of the IVAN7 9 and CATT5 trials 
were available; therefore, it was considered sensible for 
patients who experienced a greater loss of vision (≥15 
letters/three lines or more) to exit the trial to standard 
care treatment (ranibizumab or, when it became avail-
able, Eylea).
Time to visual deterioration was chosen as the primary 
outcome to allow participants to remain in the trial as 
long as they continued to respond to their treatment, 
reflecting standard NHS care. Equally, it meant that 
centres could discharge patients according to their own 
discharge policies (at which point the patient became 
censored) which was important as clinics often struggled 
with capacity, and the condition for adopting the trial was 
that there could be no additional visits over their stan-
dard care.
Secondary outcomes were VA at 9 months after rando-
misation and adverse events (AEs). VA at the 9- month 
time point was chosen to reflect the standard treatment 
discharge procedures for nAMD patients at the time of 
the trial design and meant that the trial AEs were assessed 
by site investigators for seriousness, relationship to beva-
cizumab and possible causes. All AEs were reviewed by 
the study medical monitor who was masked to participant 
treatment allocations and the independent data moni-
toring committee.
Procedures
Bevacizumab was provided by the compounding phar-
macy at the Royal Liverpool and Broadgreen University 
Hospitals NHS Trust, who undertook batch testing to 
establish the stability, potency and sterility of the bevaci-
zumab after aliquoting and storage.8 Participants initially 
received loading injections at monthly review visits for 
the first 3 months. Their vision was also measured and the 
mean of their three VA scores became their baseline VA.
They subsequently attended clinic in accordance 
with their allocated visit review schedule. Retreatment 
decisions were made on the basis of clinical and OCT 
appearances at the investigator’s discretion. VA was 
measured bimonthly and any deterioration in vision 
considered to meet the criterion for the primary outcome 
was confirmed by a refraction and repeat vision measure-
ment. Participants confirmed to have met the primary 
outcome were exited and reverted to standard NHS care.
Participants remained in the study until they either 
had visual deterioration that met the criterion for the 
primary outcome, withdrew their consent, died or their 
disease stabilised for at least 6 months without treatment 
following the initial 3 month treatment loading phase at 
investigator discretion.
Statistical analysis
The original sample size calculation assumed one study 
eye per participant, 10% annual risk of visual deteriora-
tion with standard dose bevacizumab, 10% with monthly 
review interval, no interaction between dose and review 
interval, and a non- inferiority main effects HR margin of 
1.4. With 90% power and 5% one- sided alpha, a total of 
304 events and 2000 participants was required.
The target sample size was revised in January 2014 
to 900, based on an observed annual primary outcome 
event rate of 20%, and annual censoring not previously 
included in calculations of 16%. The non- inferiority 
margin and total number of required events remained 
unchanged.
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Participants were analysed according to randomised 
allocation, regardless of adherence, following intention- 
to- treat principles, with eyes as the primary unit of 
analysis.
Cox regression with shared frailty was used for the 
primary analysis of time to vision deterioration, censoring 
participants who had not experienced the primary 
outcome at study end and accounting for inter- eye 
correlation, with eye as the unit of analysis. There was no 
evidence of any interaction between Avastin dose and visit 
review schedule. Accordingly, we estimated main effects 
of dose (low- dose vs standard- dose bevacizumab) and 
frequency (bimonthly vs monthly) by including terms for 
each in the model.23 Results are presented as HRs with 
95% CIs; low dose and bimonthly review visits would each 
be considered non- inferior if the upper 95% confidence 
limit for the respective adjusted HRs did not exceed 1.4.
Analysis of visual acuity at 9 months follow- up was 
performed using a mixed- effect model adjusted for base-
line VA score and study centre as a random effect.
We investigated subgroup effects on the primary 
outcome according to: (1) baseline VA (≤62, >62); (2) 
baseline choroidal neovascularization (CNV) size (≤4, 
>4); (3) nAMD lesion composition (classic CNV no 
occult, classic CNV and occult, occult no classic CNV). 
These analyses were conducted by fitting appropriate 
interaction terms to the primary regression model.
AEs and serious AEs were summarised descriptively by 
treatment group.
The trial was registered: ISTRCN95654194 and 
EudraCT 2009-014280-38.
Table 1 Baseline data†
Group L1 Group S1 Group L2 Group S2
Total








(n=204) (n=203) (n=203) (n=202) (n=812)
Age at enrolment (years)
  Mean (SD) 79 (7.5) 80 (7.6) 80 (7.4) 81 (7.0) 80 (7.4)
  Min, max 54–95 54–98 60–99 62–101 54–101
Gender
  Male 84 (41) 85 (42) 85 (42) 93 (46) 347 (43)
  Female 120 (59) 118 (58) 118 (58) 109 (54) 465 (57)
Smoking history
  Current smoker 29 (14) 27 (13) 21 (10) 25 (12) 102 (13)
  Ex- smoker 108 (53) 104 (51) 103 (51) 103 (51) 418 (51)
  Never smoked 67 (33) 72 (35) 79 (39) 74 (37) 292 (36)
Considered primary eye
  Right 104 (51) 108 (53) 95 (47) 101 (50) 408 (50)
  Left 100 (49) 95 (47) 108 (53) 101 (50) 404 (50)
Visual acuity at baseline (visit A)
  Primary eye mean (SD) 56.1 (15.1) 56.2 (14.0) 56.7 (13.3) 56.0 (13.9) 56.3 (14.1)
  Median (IQR) 60 (48–67) 59 (50–67) 60 (49–67) 59 (48–67) 59 (48–67)
  Min, max 20–83 8–80 25–89 16–78 8–89
  n 200 199 201 199 799
  Fellow eye mean (SD) 60.0 (12.7) 59.1 (14.9) 62.0 (12.2) 62.0 (10.1) 60.9 (12.5)
  Median (IQR) 64.5 (56–67.5) 63 (50–69) 62 (53–72) 62.5 (57–69) 63 (55–69)
  Min. max 27–85 21–79 36–83 28–78 21–85
  n 32 25 22 26 105
Primary eye distance visual acuity*
  Mean (SD) 58.7 (15.9) 58.3 (14.4) 59.4 (12.8) 58.3 (14.3) 58.7 (14.4)
  Median (IQR) 64 (49.5–70) 60 (51–70) 62 (50–69) 63 (50–70) 63 (50–70)
  Min, max 14–83 14–83 23–86 18–81 9–86
  n 200 199 201 199 799
*Mean of visual acuity at loading dose visit A, B and C.
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Role of the funding source
The funders of the study had no role in the study conduct, 
analysis or reporting. The corresponding author had 
access to all the data and has full responsibility for the 
decision to submit for publication.
RESULTS
The trial is reported in accordance with the Consolidated 
Standards of Reporting Trials guidelines for reporting 
non- inferiority trials.24
Between 3 November 2010 and 31 March 2017 
(recruitment suspended between 29 November 2011 
and 15 May 2012), 1405 patients were approached for 
trial participation, of whom 812 (918 eyes) consented 
and were randomised into the trial (figure 1). On trial 
completion, the VA data for trial participants were retro-
spectively audited for quality, and eleven participants (14 
eyes) were excluded from the primary analysis as their 
data could not be verified.
Participant baseline characteristics were well balanced 
across the groups (table 1, online supplemental table 1). 
There was an equal distribution of left and right primary 
eyes (404 and 408, respectively) and the mean VA at entry 
ranged from 56.0 to 56.7 letters across the four groups. As 
expected, most participants were ex or current smokers 
(totalling 64%) with a mean participant age of 80 years.
Eighty- nine per cent of review visits were performed 
within the pre- specified time windows, (28–42 days for 
monthly and 56–70 days for bimonthly) with a mean 
between group difference of 17.35 days (35.7 days 
between visits for monthly and 53.05 days for bimonthly). 
We noted the difference of number of injections per 
primary eye between the two groups was approximately 
two (8.75 injections for monthly and 6.9 for bimonthly). 
Twenty- nine participants initially reported as having met 
the primary outcome criterion for visual deterioration 
were found, on review, to have their VA scores incorrectly 
calculated and were censored.
FFA were taken on 787 of the 918 trial eyes and these 
were independently assessed by CARF and agreed with 
diagnosis in 97%. The 22 discordant eyes remained in 
the trial and kept their original allocation.
Primary outcome
The number of participants with the primary outcome 
and reasons for vision deterioration are presented in 
table 2. The time to trial exit was similar for all four 
groups, with a median (IQR) time of 15 (9–27) months.
The median survival time (time when half the partici-
pants are expected to experience deterioration) was 1166 
days (3.2 years) for the low dose vs 1300 days (3.6 years) 
for standard dose and 1099 days (3.0 years) for bimonthly 
review vs 1321 days (3.6 years) for monthly review.
Overall, 31% of study eyes (283/904) experienced 
visual deterioration: 32% (145/455) for low dose 
compared with 31% (138/449) for standard dose and 
36% (160/448) for bimonthly review compared with 27% 
(123/456) for monthly review. Vision deterioration was 
similar in the low and standard doses (adjusted HR 1.07; 
95% CI 0.80 to 1.42) with upper 95% confidence limit 
borderline for the prespecified non- inferiority margin 
of 1.4 (figure 2). Vision deterioration was higher for 
the bimonthly review schedule compared with monthly 
review (adjusted HR 1.45; 95% CI 1.09 to 1.94), indi-
cating that non- inferiority was not demonstrated. There 
was no evidence of any differential subgroup effects of 
either dose or frequency (figure 3).
Fourteen patients lost more than 15 letters during the 
loading regimen; 2 in the low- dose arm and 12 in the 
standard dose arm.
Secondary outcomes
There was no evidence of any between- group differences 
in VA at 9 months, with differences in means of less than 
one letter (table 3). Although some participants had 
already exited the trial due to having met the primary 
Table 2 Primary analysis: number of vision deterioration events
No of vision deterioration events
Group L1
Low dose, monthly 
schedule (n=204)
Group S1
Standard dose, monthly 
schedule (n=203)
Group L2
Low dose, bimonthly 
schedule (n=203)
Group S2
Standard dose, bimonthly 
schedule (n=202)
All eyes 62/232 (27%) 61/224 (27%) 83/223 (37%) 77/225 (34%)
Primary eye 56/200 (28%) 56/199 (28%) 73/201 (36%) 72/199 (36%)
Fellow eye 6/32 (19%) 5/25 (20%) 10/22 (45%) 5/26 (19%)
Unrelated to age related 
macular degeneration
0 1 (<0.5%) 1 (<0.5%) 1 (<0.5%)
Retinal pigment epithelium rip 3 (1%) 1 (<0.5%) 1 (<0.5%) 2 (1%)
Development of atrophy 9 (4%) 7 (3%) 11 (5%) 8 (4%)
Other 4 (2%) 3 (1%) 3 (1%) 5 (2%)
Reason for visual deterioration 
not recorded
7 (3%) 9 (4%) 5 (2%) 7 (3%)
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outcome at 9 months follow- up and are missing from this 
analysis, this was similar in all groups.
Adverse events
A large number of AEs were reported but few adverse 
reactions (online supplemental table 5). The only 
difference noted between the groups relates to more 
conjunctival haemorrhages and injection site reactions 
reported in the monthly regimen.
DISCUSSION
The results show some evidence that the low dose of beva-
cizumab was not non- inferior to standard dose; the upper 
confidence limit only just exceeded the pre- defined 
non- inferiority HR of 1.4. So, in practice, the low and 
standard doses may be viewed as similarly effective. It was 
not demonstrated that the bimonthly review arms were 
non- inferior to the monthly review arms.
Since trial inception, a number of trials5–8 23 25–27 have 
demonstrated that bevacizumab is as effective as ranibi-
zumab in the treatment of nAMD. The TANDEM trial 
provides evidence that low dose bevacizumab is similarly 
effective to standard dose. Recently, NICE concluded that 
there were no clinically significant differences in safety3 
between the bevacizumab and other agents. We found no 
evidence for a difference in safety between the low dose 
and standard dose regimens.
We observed that the number losing ≥15 letters (three 
lines) of vision during the induction phase was greater in 
the standard dose compared with the low dose (12 cases 
vs 2 cases), which was unexpected. Sudden loss of three 
lines of vison is usually due to subretinal bleeding and it 
can be speculated that this is a rare consequence of blood 
vessel regression and so it is possible that it is causally 
related to use of the higher dose.
It has become clear that these treatments do not 
completely stabilise the disease and that vision deterio-
rates over time, and this was noted here. Our observed 
rates of visual loss were comparable to other reports.27 
The SEVEN- UP study which included the original 
cohorts from the ANCHOR and MARINA studies showed 
an average of 19.8 letters lost between years 2 and 7 of 
follow- up which gives a rate of visual loss of about four 
letters per year.28 The long- term follow- up for CATT 
patients showed a loss of 11 letters from the end of year 
2 to end of year 5 which equates to 3.6 letters per year. 
The rate of vision loss was significantly greater for those 
that had received ranibizumab compared with those who 
received bevacizumab.29
Figure 2 Kaplan- Meier plots of the survival curves for (A) 
low dose versus standard dose and (B) bimonthly versus 
monthly review. A table of the number at risk is shown 
beneath the graph. There was no evidence of interaction 
between dose and review schedule (interaction HR 1.31; 
95% CI 0.73 to 2.36).
Figure 3 Subgroup analyses for the primary outcome. 
Forest plots showing the adjusted HRs and the 2- sided 
95% CI. All models adjusted for each intervention and study 
centre. The red dashed line indicates the HR=1.4 non- 
inferiority margin. Not all participants had the CARF data 
so the total number of eyes differs for each model. CARF, 
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In this study, the median time to event (losing five letters 
from the average of the VA during the loading period) 
was 3 years for the bimonthly review arms and 3.6 years 
for the monthly review arms for those with active disease, 
equating to a difference of under half a letter per year 
in the rate of visual loss of between the regimens. This 
difference is of uncertain clinical significance and both 
monthly and bimonthly as required (PRN) regimens can 
be considered effective in the treatment of nAMD; the 
more intensive (monthly review regimen) may be appro-
priate for patients at a critical threshold where the loss of 
a couple of letters would be significant. However, some 
patients may accept a slightly worse outcome as they 
prefer a less intensive review regimen.30
The median number of injections per participant was 
5–6 (online supplemental table 4), which was fewer than 
in other studies and yet the results were comparable, 
suggesting that there may be a tendency to overtreat. The 
FLUID study showed that subretinal fluid could be safely 
observed in selected cases, showing that it is not always 
an indicator of active disease.31 Here, it was observed that 
there were more macular haemorrhages causing severe 
visual loss in the standard arms during the induction 
phase. This was an unexpected observation but suggests 
that in some cases, haemorrhage may be due to blood 
vessel regression and not due to disease activity.
A particular advantage of the PRN regimens is that 
it allows early recognition of inactive disease thereby 
preventing over treatment. A disadvantage is that those 
with active disease may get under treated. A compromise 
position is to consider treating those with active disease 
with a ‘mini- course’. The PRN regimens in the CATT 
study5 6 did slightly less well than those given monthly 
injections where a single injection was given if there was 
disease activity. In the IVAN PRN group, retreatment 
when required was given by a course of 3 monthly injec-
tions, and there was no difference noted between the 
PRN and monthly groups.7 8 The VIEW 1 and 2 studies 
showed that aflibercept was not inferior to ranibi-
zumab17 32 and can be given bimonthly on a continuous 
basis.
Strengths of this study were the inclusive nature of the 
study population and the length of follow- up. As a prag-
matic trial, TANDEM included all patients who met the 
criteria for standard care anti- VEGF treatment. Patients 
who declined to have a FFA but were still thought to have 
nAMD were still eligible for enrolment into TANDEM; 
86% did have a pretreatment FFA and in 97% of these, 
the diagnosis was confirmed by CARF.
All previous trials have been limited to 1–2 years which 
meant that long- term visual deterioration could not be 
observed. As a time- to- event trial, participants remained 
in the trial with active disease for up to 5 years, allowing 
assessment of the long- term outcomes for the majority 
of participants. In contrast, there were a subset of partic-
ipants (n=176) who could not be followed to vision 
deterioration or stable disease as they remained disease 
active at the point the trial ended.
The trial had limitations. The time- to- event trial design 
is unusual for nAMD trials and has made it difficult to 
directly compare results with previous research. The 
design was chosen for reasons of patient safety; it enabled 
anyone with visual deterioration to be exited early from 
the trial back to routine NHS care. This was appropriate 
Table 3 Secondary outcome of visual acuity at 9 months postrandomisation
Group L1 Group S1 Group L2 Group S2








(n=204) (n=203) (n=203) (n=202)
Distance visual acuity for all eyes:
  Mean (SD) 62.4 (16.9) 63.9 (16.3) 63.5 (14.2) 63.4 (15.2)
  n 200 177 182 187
Distance visual acuity for primary eye
  Mean (SD) 61.8 (17.1) 63.8 (16.1) 63.1 (14.2) 63.1 (15.3)
  n 174 157 167 169
Distance visual acuity for fellow eye
  Mean (SD) 65.9 (15.7) 64.5 (17.9) 68.1 (13.8) 65.7 (15.2)
  n 26 20 15 18
Comparison Adjusted differences in mean* 95% CI
Low dose (L1+L2) vs standard dose (S1 
+S2)
−0.96 −2.08 to 0.17
Bimonthly (L2+S2) vs monthly (L1+S1) 0.13 −0.99 to 1.25
Interaction between dose and schedule 0.97 −1.27 to 3.22
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at the time of trial design since the trials demonstrating 
non- inferiority of bevacizumab had not been reported.
The trial was designed to run in parallel with routine 
NHS care, and all services were (and are) struggling 
with capacity. This meant that centres had to discharge 
patients who were thought to have inactive disease and 
so the long- term results are in terms of those with ‘active 
disease’ rather than the total population.
This study has shown that although the upper confi-
dence limit just exceeded the predefined non- inferiority 
HR of 1.4, low and standard doses might in practice be 
viewed as similarly effective in the treatment of nAMD.
The study did not provide evidence that bimonthly 
PRN regimen is non- inferior to monthly. Continuous 
regimens run the risk of over treatment and PRN of 
under treatment. NICE modelled the existing regimens 
and concluded that there was little difference between 
any of the commonly used ones; but this remains an area 
for future research.
Research in context
TANDEM is the UK’s largest nAMD clinical trial (and 
one of the largest conducted worldwide) with the partic-
ipants accurately reflecting the NHS patient population. 
TANDEM was unique in that it was embedded within 
ophthalmology clinics and was the vehicle for delivery 
of routine NHS care. This design allowed for prolonged 
observation of participants of up to 5 years, exceeding 
previous trials where follow- up typically ended at the 1 
or 2 year time point. This is particularly relevant as it is 
after 2 years of treatment that visual outcomes have been 
shown to drop off.
TANDEM is the only trial to date that has directly inves-
tigated whether a bimonthly bevacizumab regimen is 
non- inferior compared with a monthly treatment. This 
has been given particular relevance recently as bimonthly 
bevacizumab is the only nAMD treatment regimen that 
met the NICE criteria for cost- effectiveness on their 
health economic model (though they have approved 
other regimens).
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SUPPLEMENTARY TABLE 1:  Baseline Data 
 
 Group L1 
(n = 204) 
Group S1 
(n = 203) 
Group L2 





Age at enrolment (years):  
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Neovascular lesion involving the centre of fovea 
Primary eye 
































































































































































Ace inhibitors  









































Visual acuityA at baseline (visit A)  
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 Group L1 
(n = 204) 
Group S1 
(n = 203) 
Group L2 


















CV size (area) 









































































































Classic CNV, no occult 
Classic CNV and occult 












Classic CNV, no occult 
Classic CNV and occult 
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 Group L1 
(n = 204) 
Group S1 
(n = 203) 
Group L2 





















































Diagnosis of CNV 
















































*All data are n (%) unless otherwise indicated. 
†mean of visual acuity at loading dose visit A, B and C 
‡ Number of participants included in the table that satisfy the criteria, but did not exit when reaching event = four (due to 
different criteria in earlier version of protocol - changed 22 Sept 2011); two at visit B and two at visit C. 
Treatment key: L1 = low dose, once a month schedule; S1 = standard dose, once a month schedule; L2 = low dose, bi-
monthly schedule; S2 = standard dose, bi-monthly schedule 
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SUPPLEMENTARY TABLE 2:  Total number of injections per primary eye, time in 
trial, and between visit duration 
 Group L1 
(n = 204) 
Group S1 































6 (4, 10) 
1, 47 








Mean (SD) 47.6 (29.5) 50.2 (35.8) 45.4 (29.5) 48.2 (32.4) 47.9 (31.9) 
Median (IQR) 38.2 (24.3, 68.8) 38.5(22.2, 75.3) 36.2 (24.2, 62.3) 40 (23.9, 66.8) 38.2 (23.3, 68.0) 
Min, max 0.1, 133.4 2.3, 165.7 8.9, 164.5 0.1, 172.7 0.1, 172.7 
      











Mean (SD) 35.9 (5.5) 35.5 (4.2) 52.6 (6.9) 53.5 (7.4) 44.4 (10.6) 
Median (IQR) 35.2 (33.5, 38.3) 35 (33.1, 37.6) 53.7 (49, 57.8) 53.9 (50, 58) 42 (35, 53.9) 
Min, max 23.3, 87.5 17.5, 54.4 28, 79.3 28, 77 17.5, 87.5 
n 199 200 201 200 800 
* All participants should receive three loading doses, before the maintenance phase 
Treatment key: L1 = low dose, once a month schedule; S1 = standard dose, once a month schedule; L2 = low dose, bi-
monthly schedule; S2 = standard dose, bi-monthly schedule 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Ophth
 doi: 10.1136/bmjophth-2020-000588:e000588. 5 2020;BMJ Open Ophth, et al. Foss A
SUPPLEMENTARY TABLE 3:  Adverse Events and Serious Adverse Events 








Number of participants reporting adverse event from first dose of trial treatment – 10 most 
frequent 
Event category (preferred term) No. (%) No. (%) No. (%) No. (%) 
Fall 35 (17.2) 43 (21.2) 28 (13.8) 29 (14.4) 
Lower respiratory tract infection 28 (13.7) 25 (12) 27 (13.3) 26 (12.9) 
Injection site reaction
†
 20 (9.8) 24 (11.8) 12 (5.9) 12 (5.9) 
Visual acuity reduced
†
 23 (11.3) 18 (8.9) 13 (6.4) 13 (6.4) 
Conjunctival haemorrhage
†
 18 (8.8) 17 (8.4) 12 (5.9) 10 (5.0) 
Eye pain
†
 12 (5.9) 13 (6.4) 13 (6.4) 10 (5.0) 
Urinary tract infection 12 (5.9) 16 (7.9) 10 (4.9) 10 (5.0) 
Headache 9 (4.4) 20 (9.9) 11 (5.4) 8 (4.0) 
Dizziness 8 (3.9) 15 (7.4) 10 (4.9) 11 (5.4) 
Nasopharyngitis 11 (5.4) 15 (7.4) 9 (4.4) 5 (2.5) 
Number of adverse events from first dose of trial treatment – 10 most frequent‡ 
Fall 56 66 34 53 
Lower respiratory tract infection 36 37 36 46 
Injection site reaction 24 30 14 12 
Visual acuity reduced 25 18 16 16 
Urinary tract infection 15 20 18 16 
Eye pain 11 30 13 8 
Conjunctival haemorrhage 19 17 12 10 
Headache 15 16 14 12 
Dizziness 12 17 11 13 
Nasopharyngitis 13 22 11 5 
Number and type of serious adverse events    
SAE 81 69 83 83 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Ophth
 doi: 10.1136/bmjophth-2020-000588:e000588. 5 2020;BMJ Open Ophth, et al. Foss A
SAR 4 6 4 4 
SUSAR 3 1 2 1 
TOTAL 88 76 83 88 
 
All data are n (%) unless otherwise indicated. 
†
Thought to be related to treatment 
‡
 All data are n unless otherwise indicated. 
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